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Huntington’s disease (HD) is a neurodegenerative
disease characterized in part by the loss of striatopal-
lidal medium spiny projection neurons (MSNs).
Expression of BDNF and noggin via intracerebroven-
tricular (ICV) delivery in an adenoviral vector triggers
the addition of newneurons to the neostriatum. In this
study, we found that a single ICV injection of the
adeno-associated viruses AAV4-BDNF and AAV4-
noggin triggered the sustained recruitment of new
MSNs in both wild-type and R6/2 mice, a model of
HD. Mice treated with AAV4-BDNF/noggin or with
BDNF and noggin proteins actively recruited sub-
ependymal progenitor cells to form new MSNs that
matured and achieved circuit integration. Impor-
tantly, the AAV4-BDNF/noggin-treated R6/2 mice
showed delayed deterioration of motor function and
substantially increased survival. In addition, squirrel
monkeys given ICV injections of adenoviral BDNF/
noggin showed similar addition of striatal neurons.
Induced neuronal addition may therefore represent
a promising avenue for disease amelioration in HD.
INTRODUCTION
Huntington’s disease (HD) is an autosomal-dominant neurode-
generative disorder characterized by progressive impairment
of motor function and cognition and an invariably fatal outcome.
HD is characterized by the progressive loss of both cortical and
subcortical neurons, as most markedly reflected in the loss of
striatal medium spiny neurons (MSNs) and consequent striatal
atrophy. In previous studies in adult rodents, we found that
new MSNs may be generated from resident subependymal neu-
ral stem cells by concurrent overexpression of BDNF and noggin
(Benraiss et al., 2001; Chmielnicki et al., 2004). The newly gener-atedMSNs established axonal projections to their normal targets
in the globus pallidus and proved able to temporarily slow dis-
ease progression and extend life span in R6/2 mice, a murine
model of HD (Cho et al., 2007). Yet these prior studies had
demonstrated neither the functional integration of these new
neurons nor their sustained therapeutic value. Furthermore, the
practical therapeutic value of the adenoviral approach used for
BDNF and noggin delivery was limited by the transient expres-
sion and immunogenicity of adenoviral vectors (Dai et al.,
1995). To overcome these limitations, we used adeno-associ-
ated virus serotype 4 (AAV4), a vector that is neither immuno-
genic nor neurotoxic, to achieve sustained BDNF and noggin
expression. Using two AAV4s constructed to overexpress
BDNF and the DB2 mutein of noggin (Paine-Saunders et al.,
2002), we found that their combined delivery resulted in the sus-
tained ependymal overexpression of BDNF and noggin, which in
turn led to persistent neuronal addition to the rat neostriatum for
at least 4 months (Benraiss et al., 2012).
On the basis of these studies, in the present study we asked
whether AAV4-BDNF and AAV4-noggin (AAV4-BDNF/noggin)
coexpression might be used to drive the sustained addition of
new MSNs to the neostriata of R6/2 huntingtin mutant mice.
We found that bilateral intraventricular injections of AAV4-
BDNF/noggin indeed triggered substantial and sustained MSN
addition to the striata of R6/2 mice and that mice so treated ex-
hibited a delay in disease progression, as manifested by both
improved motor coordination and significantly extended life
span. Furthermore, using inducible nestin-CreERT2/ROSA26/
EYFP mice crossed to R6/2 mice and injected with a retrograde
tracer to investigate the origin and connectivity of the newly
generated neurons, we found that the cells expressed prototypic
markers of mature MSNs and successfully extended projections
to the globus pallidus. Using this model, we then assessed the
electrophysiological properties of the newly generated neurons
and found that they matured as typical MSNs, which were phys-
iologically indistinguishable from resident striatal neurons. Thus,
intraventricular delivery of AAV4-BDNF/noggin, and its associ-
ated induction of sustained striatal neuronal recruitment, may
comprise a promising therapeutic treatment for HD.Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc. 787
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AAV4 Drives Transgene Expression Limited to the
Ventricular Wall of the Adult Forebrain
To achieve the long-term expression of BDNF and noggin in the
brain, we used an AAV4-based transfer vector, based upon
AAV4’s predilection for ependymal cells within the adult brain
(Liu et al., 2005). In normal adult mice, we first used immunoflu-
orescence to identify AAV4-EGFP (AAV4-Null)-transduced cells
8 weeks after intracerebroventricular (ICV) viral injection. The
GFP+ cells were restricted to the ependymal wall of the lateral
ventricle (Figure S1 available online), reproducing the expression
pattern noted after ICV injection into adult rats (Benraiss et al.,
2012). No parenchymal EGFP expression was noted, nor did
we find any evidence of EGFP+ cells in the olfactory bulb, sug-
gesting that the neural stem cells of the subventricular zone
(SVZ) were not transduced; rather, transgene expression
appeared limited to the ependymal cell layer lining the ventricular
lumen. Accordingly, immunostaining for BDNF protein revealed
that BDNF overexpression in AAV4-BDNF/noggin-treated striata
was both strong and largely limited to the ventricular lining
(Figure S1).
To assess the levels of BDNF/noggin released into the CSF,
4-week-old mice received bilateral injections of either AAV4-
BDNF/noggin, AAV4-Null, or saline (n = 6/group). Eight weeks
later, the mice were sacrificed with CSF withdrawal via cisternal
tap, and their BDNF and noggin levels were quantified by ELISA.
Among the AAV4-BDNF/noggin-treated mice, CSF BDNF levels
averaged 1 ± 0.1 ng/ml CSF (0.7 ± 0.05 ng/mg protein; mean ±
SEM), while noggin achieved 8.4 ± 0.2 ng/ml CSF (6.2 ±
0.2 ng/mg protein; mean ± SEM). In contrast, neither BDNF nor
noggin were detectable in the CSF of any AAV4-Null or saline-
treated animals (Table S1). These data indicated that AAV4-
mediated intracerebral delivery was sufficient to drive the sus-
tained CSF production of BDNF and noggin in the adult mouse
brain at levels previously demonstrated (Chmielnicki et al.,
2004; Cho et al., 2007) to be sufficient for the induction of striatal
neuronal addition.
AAV4-BDNF/Noggin-Treated R6/2 Mice Recruited New
Striatal Neurons
We next asked if intraventricular injection of AAV4-BDNF/noggin
was sufficient to induce the addition of new neurons in R6/2
mice. We gave bilateral ICV injections of AAV4-BDNF/noggin
(n = 13), AAV4-EGFP (AAV4-Null, n = 16), or saline (n = 15) to
4-week-old R6/2 mice. The viral titer was adjusted to 1.3 3
1012 viral genomes (vg)/ml, and 1.5 ml of viral suspension con-
taining 1.85 3 109 vg was then injected into each ventricle.
Beginning 2 weeks after viral injection, all mice were given daily
BrdU injections (75 mg/kg) for 4 weeks. The mice were then
sacrificed 2 weeks after the last BrdU injection, at 12 weeks of
age, to permit sufficient time for the maturation and integration
of newly generated neurons. Immunostained cryosections of
AAV4-BDNF/noggin-treated brains revealed striatal BrdU+ neu-
rons, which expressed the early neuronal markers doublecortin
(Dcx) and ßIII-tubulin (TuJ1). In addition, many BrdU+ striatal
neurons coexpressed the mature neuronal antigens NeuN and
DARPP-32, the latter indicating their maturation as MSNs
(Figure 1).788 Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc.Stereological analysis revealed that AAV4-BDNF/noggin-
treated R6/2 mice harbored significantly more Dcx+/BrdU+ cells
than either their AAV4-Null or saline-treated controls (228 ± 42.8,
versus 43 ± 14.5 and 31 ± 9.2 Dcx+/BrdU+ cells/mm3, respec-
tively; mean ± SEM, p < 0.001 by one-way ANOVA with Bonfer-
roni post hoc tests) (Figure 1A). Similarly, ßIII-tubulin/BrdU+
neurons were found in significantly higher numbers in R6/2
mice treated with AAV4-BDNF/noggin compared to those
treated with AAV4-Null or saline (AAV4-BDNF/noggin: 194 ±
30.8; AAV4-Null: 16 ± 7.0; saline: 5 ± 5.0 ßIII-tubulin+/BrdU+
cells/mm3; mean ± SEM; p < 0.001) (Figure 1B). Importantly,
whereas small numbers of immature neurons were noted in the
striata of AAV4-Null or saline-treated R6/2 mice, no newly gener-
ated neurons progressed to mature phenotype in these control
mice. Thus, AAV4-BDNF/noggin-treated mice harbored signifi-
cantly more NeuN+/BrdU+ striatal neurons than did their AAV4-
Null or saline controls (58.5 ± 14.2 versus 0 ± 0 and 0 ±
0 NeuN+/BrdU+ cells/mm3, respectively; mean ± SEM; p <
0.01) (Figure 1C). Similarly, DARPP-32+/BrdU+ neurons were
found only in AAV4-BDNF/noggin-treated R6/2 mice, and not
in their AAV4-Null or saline-treated R6/2 controls (53 ± 15.5,
0 ± 0, and 0 ± 0 DARPP-32+/BrdU+ cells/mm3, respectively;
mean ± SEM, p < 0.01) (Figure 1D and Table S2). It is worth
noting that Dcx+/BrdU+ cells were much more abundant than
NeuN+/BrdU+ or DARPP-32+/BrdU+ cells. This may be in part
due to the expression of Dcx by glial progenitor cells (Sim
et al., 2006; Tamura et al., 2007). More broadly though, our
data suggest that not all newly generated neuroblasts survive
to maturity in these mice, and the fraction of newly generated
neurons that do so is a dynamic and regulated function of their
exposure to BDNF and noggin.
We next asked whether treatment with AAV4-BDNF/noggin
affected striatal neuronal number or morphometrics. To this
end, AAV4-BDNF/noggin or AAV4-Null-treated R6/2 mice and
theirwild-type littermates (four groups; n = 7/group)were injected
at 4 weeks and sacrificed at 12 weeks. Cryosections of their
striata were immunostained for neuronal NeuN, and both
NeuN+ neuronal counts and striatal volumeswere then stereolog-
ically estimated (Figure S2). No differences were noted in total
striatal neuronal numbers across groups, including between our
R6/2-105CAGrepeatmiceand theirwild-typecontrols, reflecting
previous reports that R6/2-150 CAG mice undergo little if any
striatal neuronal loss (Cho et al., 2007; Davies et al., 1997; Tur-
maine et al., 2000). In addition, no effect of AAV4-BDNF/noggin
treatment was noted on the terminal neuronal counts of either
R6/2 mice or their wild-type controls (p > 0.05, two-way ANOVA
withBonferroni post hoc tests) (Figure S2A). This was not surpris-
ing, given the relatively small fraction of thewhole represented by
the newly generated population, and the unclear fate of diseased
resident neurons when joined by newly generated cells.
Despite their stable neuronal numbers, the R6/2-105 CAG
mice used in this study exhibited significant striatal involution
relative to their wild-type littermates; this too has previously
been noted in R6/2-150 CAG mice (Cho et al., 2007; Davies
et al., 1997; Turmaine et al., 2000). As a result, the AAV4-Null-
treated R6/2 mice displayed higher neuronal densities than did
their wild-type counterparts (21.1 3 104 ± 1.9 3 104 versus
14.1 3 104 ± 1.1 3 104 neurons/mm3, respectively; mean ±
SEM, p < 0.05, two-way ANOVA with post hoc Bonferroni post
Figure 1. Newly Generated Neurons Mature into Medium Spiny Neurons
Striatal sections of AAV4-BDNF/noggin-treated R6/2 mice, sacrificed 8 weeks after viral injection. Sections were immunostained for BrdU (green) and one of the
following neuronal markers: Doublecortin (A1), ßIII-tubulin/TuJ1 (B1), NeuN (C1), DARPP-32 (D1), enkephalin (E1), or substance P (F1) (all in red). Double-
immunolabeled cells were confirmed as such by confocal imaging, with orthogonal views in the x-z and y-z planes. Stereological counts of newly generated
neurons defined by their expression of BrdU along with doublecortin (A2), ßIII-tubulin/TuJ1 (B2), NeuN (C2), DARPP-32 (D2), enkephalin (E2), or substance P (F2).
One-way ANOVA with Bonferroni post hoc tests; mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar: 10 mm. See also Figure S1 and Tables S1 and S2.
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product of neuronal atrophy and involution of the R6/2 neuropil,
which yielded higher packing densities for surviving cells.
Importantly, this higher density was reversed by AAV4-BDNF/
noggin-treatment, such that the striatal neuronal densities of
treated R6/2 mice did not significantly differ from those of the
AAV4-Null-treated wild-type mice (18.93 104 ± 1.83 104 versus
14.13 104 ± 1.13 104 neurons/mm3, respectively; mean ± SEM,
p > 0.05, one-way ANOVA with post hoc Bonferroni test)
(Figure S2B).
Newly Generated MSNs Expressed Markers of Both
Striatal Output Pathways
MSNs expressing substance P project to the globus pallidus
interna (GPi) and comprise the direct output pathway of the
basal ganglia. In contrast, enkephalin-expressing neurons
project to the globus pallidus externa (GPe) and thereby
comprise the indirect pathway. To determine the extent to which
each of these MSN phenotypes were represented among AAV4-
BDNF/noggin-induced striatal neurons, we immunostained
sections of treated mice for BrdU together with either substance
P or enkephalin. We found that new enkephalin+/BrdU+ and
substance-P+/BrdU+ neurons were both abundant and roughly
equally represented in AAV4-BDNF/noggin-treated R6/2 striata
(35 ± 14.3 enkephalin+/BrdU+ and 33 ± 14.1 substanceP+/BrdU+ cells/mm3, respectively; mean ± SEM, p < 0.05 by
one-way ANOVA with Bonferroni post hoc t test) (Figures 1E
and 1F and Table S2). This neuropeptide expression data
suggested that newly generated MSNs integrate into the
direct and indirect striatal output pathways with roughly equal
probability.
AAV4-BDNF/Noggin Treatment Delayed Disease
Progression and Extended Survival
We next asked whether AAV4-BDNF/noggin administration and
its associated induction of striatal neuronal replacement were
associated with either an amelioration of disease or a delay in
disease progression. To do so, we assessed the effects of treat-
ment on both the motor performance and survival of R6/2 HD
mice. The AAV4-BDNF/noggin-treated mice exhibitedmore sus-
tained motor performance through at least the third month post-
injection, relative to both AAV4-Null- and saline-treated controls.
The two sets of controls did not significantly differ from one
another at any time point (Figure 2A). ANOVA confirmed that
the rate of deterioration of motor performance was significantly
slowed by AAV4-BDNF/noggin treatment (F [2,187] = 15.49;
p < 0.0001; two-way ANOVA with Bonferroni post hoc tests).
To assess the survival benefit of AAV4-BDNF/noggin adminis-
tration, and inferentially of induced MSN addition, we next
evaluated the effects of treatment upon the net life span of HDCell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc. 789
Figure 2. AAV4-BDNF/Noggin Treatment
Delayed Motor Deficits and Extended Sur-
vival in R6/2 Mice
(A) AAV4-BDNF/noggin-treated R6/2 mice (n = 13)
exhibited slower deterioration of motor perfor-
mance than did AAV4-Null (n = 11) or saline-
treated (n = 10) controls. (A) plots the duration of
rotarod performance as a dual function of age and
treatment, using a 14 rpm challenge. ANOVA of
rotarod endurance versus weeks posttreatment
confirmed that the rate of deterioration of motor
performance was slowed significantly by AAV4-
BDNF/noggin (F [2,187] = 15.49; p < 0.0001; two-
way ANOVA with Bonferroni post hoc tests;
mean ± SEM; *p < 0.05, **p < 0.01).
(B) This plot illustrates the survival curves of
AAV4-BDNF/noggin-treated and untreated R6/2
mice. AAV4-BDNF/noggin (n = 18), AAV4-Null
(n = 19), or saline-treated R6/2 mice (n = 21) were
allowed to live among wild-type littermates.
Kaplan-Meier survival analysis showed that the
AAV4-BDNF/noggin-treated R6/2 mice lived a
median of 171 days, while AAV4-Null-treated and
saline controls survived only 128 and 113 days,
respectively.
See also Figure S2.
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19), or saline (n = 21) injections were administered into the lateral
ventricles of 4-week-old R6/2 mice (Figure 2B). AAV4-BDNF/
noggin treatment significantly extended the survival of these
mice, relative to the AAV4-Null or saline control animals;
ANOVA with post hoc comparisons confirmed the difference in
mean survival between AAV4-BDNF/noggin-treated R6/2 mice,
AAV4-Null-treated mice, and saline controls (Log-rank test, p <
0.0001 for each). In contrast, no significant difference was noted
in survival between the saline and AAV4-Null control groups
(Log-rank test, p = 0.69). Thus, AAV4-BDNF/noggin treatment
yielded both a slower rate of motor deterioration and substan-
tially improved survival. Of note, treatment was not associated
with any worsening of weight loss of R6/2 mice, which tends to
occur as disease progress (Mangiarini et al., 1996). As such,
we observed no significant difference in body weight that could
be attributed to AAV4-BDNF/noggin treatment at the well-toler-
ated doses and transgene expression levels achieved in this
study (age effect: F[14,312] = 7.43, p < 0.0001; treatment effect:
F[2,312] = 0.71, p > 0.05; two-way ANOVA with Bonferroni post
hoc tests; Figure S3).
Newly Generated MSNs Arise from Nestin-Expressing
Subependymal Cells
To establish whether AAV4-BDNF/noggin-induced newly gener-
ated MSNs functionally integrate into the existing striatopallidal
circuits, we asked whether these cells extend projection fibers
to the globus pallidus. Specifically, we used a fate-tracking re-790 Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc.porter mouse to establish the origin
and fate of newly generated neurons. In
brief, nestin-CreERT2/ROSA-EYFP mice
(Imayoshi et al., 2006) express a Cre re-
combinase-estrogen receptor fusion pro-tein under the control of the promoter and second intronic
enhancer of nestin, which is expressed by neural stem cells
and their immediate transit-amplifying progeny (Keyoung et al.,
2001; Lendahl et al., 1990; Mignone et al., 2004; Zimmerman
et al., 1994). Upon tamoxifen administration to adult mice,
nestin-expressing cells begin to constitutively express the
EYFP reporter, thereby permanently labeling both neural stem
and progenitor cells and all of their progeny generated after the
period of tamoxifen treatment (Figure S4).
Next, we then sought to specifically label newly generated
neurons to characterize their connectivity and functional pheno-
type. To this end, 3-week-old nestin-CreERT2/ROSA-EYFP
bigenic mice were treated with tamoxifen to activate nestin-
driven Cre recombinase; the mice then received intraventricular
injections of AAV4-BDNF/noggin and were examined 8 weeks
later, to allow sufficient time for the migration and differentiation
of newly generated neurons (Figure S5A). We found that BDNF/
noggin overexpression resulted in the robust recruitment of new
EYFP+ striatal neurons, all presumably derived from nestin-
expressing stem or progenitor cells. The EYFP+ cells also coex-
pressed both NeuN and DARPP-32 (Figures 3A and 3C),
indicating that newly generated MSNs are the progeny of
nestin-expressing subependymal cells. Stereological analysis
revealed that the striata of AAV4-BDNF/noggin-treated nestin-
CreERT2/ROSA-EYFP mice harbored significantly more
EYFP+/DARPP-32+ cells than did AAV4-Null controls (139 ±
40.3 versus 14.9 ± 4.5 EYFP+/DARPP-32+ cells/mm3, respec-
tively; mean ± SEM; p < 0.05) (Table S3).
Figure 3. Fate-Mapping Reveals the Origin and Morphologies of BDNF/Noggin-Induced MSNs
Tamoxifen-induced nestin-CreERT2/ROSA-EYFP (A, C, and E) or nestin-CreERT2/ROSA-EYFP/R6/2 (B, D, and F) transgenic mice received bilateral, intra-
ventricular injections of AAV4-BDNF/noggin at 4 weeks of age. Newly generated neurons expressed the mature and medium-spiny neuronal markers NeuN
(A and B) and DARPP-32 (C and D), respectively. (E and F) New EFYP+ neurons also integrated into the striatopallidal circuitry as revealed by their incorporation of
the retrograde tracer cholera toxin subunit B (CT-B; Alexa Fluor 555-conjugated) following receipt of intrapallidal injections. (G and H) To visualize the fine
morphologies of AAV4-BDNF/noggin-inducedMSNs, 3-week-old nestin-CreERT2/ROSA-mEGFP (membrane-targeted EGFP) mice were treated with tamoxifen
for 5 days followed by intraventricular AAV4-BDNF/noggin. The mice were sacrificed 8 weeks later (see Figure S4 for design). The expression of mEGFP by new
striatal neurons revealed their complex dendritic networks (G), which mimicked those of resident neurons expressing mEGFP following intrastriatal injection of
Lenti-CMV-mEGFP (H). Arrows indicate dendritic spines. Scale bars: (A)–(F): 10 mm; (G) and (H): 20 mm. See also Figure S4 and Tables S3A and S3B.
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To investigate the morphology of newly generated striatal neu-
rons, and to assess their acquisition of medium spiny neuronal
phenotype, we used conditionally expressed membrane-linked
EGFP (mEGFP) to visualize newly generated neurons and viral
labeling to visualize existing resident neurons. Conditional tar-
geting of newly generated neurons was done by crossing the
nestin-CreERT2 to ROSA26-mEGFP mice; this reporter ex-
presses mEGFP upon tamoxifen-triggered Cre-dependent
removal of an upstream floxed-stop. This was followed by treat-
ment with AAV4-BDNF/noggin, as described above in Fig-
ure S5A. In addition, in order to target preexisting neurons,
10-week-old wild-type mice received intrastriatal injections of
lentivirus constitutively expressing the same membrane-taggedmEGFP reporter; the mice were sacrificed 2 weeks after viral
injection. In both cases, striatal neurons could be identified by
their expression of mEGFP-reported fluorescence, which re-
vealed that newly generated neurons shared with their preexist-
ing counterparts the prototypic morphologies of MSNs. We
found that the dendritic spine morphologies and densities of
new and preexisting resident neurons were indistinguishable
from one another (Figures 3G and 3H). Statistical analysis did
not reveal any difference in spine numbers on dendrites
(11.7 ± 0.9 and 11.2 ± 0.5 spines/10 mm dendritic length,
for newly generated and preexisting neurons, respectively;
mean ± SEM; n = 7 neurons each; p > 0.5, t = 0.55). Thus, newly
generated neurons are morphologically indistinguishable from
preexisting MSNs, in both their gross morphology and dendritic
spine densities.Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc. 791
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Having demonstrated the origins and maturation of newly
generated MSNs in wild-type nestin-CreERT2/ROSA-EYFP
reporter mice, we next asked whether these mice could be
crossed to R6/2 mice to allow the tracking of newly generated
neurons in the adult diseased brain. We found that the resultant
triple transgenic mice, after receiving a 10 day regimen of
tamoxifen beginning at 3 weeks of age and injected with
AAV4-BDNF/noggin (n = 4) or AAV4-Null (n = 3) at 4 weeks of
age, exhibited the robust neostriatal addition of tagged neurons
when assessed at 12 weeks of age. In particular, the AAV4-
BDNF/noggin-treated triple transgenic mice showed substan-
tial recruitment of new EYFP+ MSNs, as evidenced by their
coexpression of EYFP together with either NeuN or DARPP-
32 (Figures 3B and 3D). Importantly, AAV4-BDNF/noggin-
associated neuronal addition was at least as pronounced in
nestin-CreERT2/ROSA-EYFP/R6/2 trigenic mice as in healthy
wild-type nestin-CreERT2/ROSA-EYFP controls (212.6 ± 60.8
EYFP+/DARPP-32+ versus 139 ± 40.2 cells/mm3, respectively;
mean ± SEM; p < 0.05). Statistical analysis confirmed the signif-
icant effect of AAV4-BDNF/noggin in inducing neuronal addition
and that R6/2 mice exhibited this effect as strongly as their
wild-type counterparts (treatment effect: F [1,8] = 23.70, p <
0.01; genotype effect: F [1,8] = 2.11, p > 0.05; two-way
ANOVA with Bonferroni post hoc tests) (Table S3). Of note,
we reproducibly detected evidence of neuronal addition in
AAV4-Null R6/2 mice, which exhibited 48.5 ± 10.7 EYFP+/
DARPP-32+ cells/mm3 (mean ± SEM; Table S3); this appeared
to reflect an element of compensatory neuronal addition in the
HD environment, as we have previously noted in adenoviral
Null-treated R6/2 mice (Cho et al., 2007), and which has been
similarly reported in human autopsy samples (Curtis et al.,
2003).
Newly Generated MSNs Extend Axonal Projections to
the Globus Pallidus
In previous studies, we noted that newly generated
MSNs recruited in response to adenoviral BDNF and noggin
overexpression can extend projections to their pallidal targets.
To confirm that AAV4-BDNF/noggin-induced neurons
similarly develop pallidal axonal projections, virally treated
bigenic nestin-CreERT2/ROSA-EYFP and trigenic nestin-
CreERT2/ROSA-EYFP/R6/2 mice (n = 4 each) were all given
intrapallidal injections of a retrograde tracer, Alexa Fluor 555-
conjugated cholera toxin subunit B (CT-B), 1 week before
their sacrifice at 12 weeks of age (Figures S5A and S5B).
Many newly generated EYFP+ neurons incorporated the CT-B
retrograde tracer after receiving intrapallidal injections,
indicative of their successful projection to the globus
pallidus, as typical of medium spiny phenotype (Figures 3E
and 3F). To rule out any labeling of striatal MSNs by diffusion
of the tracer rather than a retrograde incorporation, we also
stained for choline acetyltransferase (ChAT), a marker for
cholinergic nonprojecting striatal interneurons. Confocal anal-
ysis showed no CT-B accumulation within the cell bodies of
ChAT-immunoreactive neurons of the striatum, underscoring
the lack of diffusion of the tracer from the site of injection
(Figure S5C).792 Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc.New Striatal Neurons Mature as Physiologically Active
Projection Neurons
To investigate the ability of newly generated neurons to function-
ally integrate into the striatopallidal circuitry, we next asked if
they developed afferent synaptic input and were competent to
generate action potentials. To this end, we performed whole-
cell electrophysiological recording. Due to the attenuated visibil-
ity of EYFP within live tissue, we crossed the nestin-CreERT2
mice with a ROSA-CAG-EYFP reporter mouse in which the
EYFP is directed by the relatively strong CAG (chicken b-actin)
promoter; this yields more intense EYFP expression upon
removal of the floxed stop (Madisen et al., 2010). Three-week-
old nestin-CreERT2/ROSA-CAG-EYFP mice received daily
tamoxifen injections for 5 days; 2 days later, and at 4 weeks of
age, an osmotic micropump that continuously infused BDNF
and noggin protein over the ensuing 14 days through the end
of their sixth week of age was implanted into the lateral ventricle.
One week later, the mice were given an intrapallidal injection of
Alexa Fluor 594-conjugated CT-B as a retrograde tracer in order
for us to identify those new neurons that successfully integrated
into the striatopallidal circuitry. The mice were then sacrificed at
8 weeks of age, and two-photon-assisted patch-clamp record-
ings were performed on 300 mm coronal vibratome sections,
as described (Bekar et al., 2008; Kang et al., 1998) (Figure 4A).
New projection neurons (EYFP+) that incorporated the red fluo-
rescent tracer (CT-B+) were subjected to whole patch-clamp in
current-clamped configuration, and their responses to increased
current steps were recorded and compared to that of CT-B+/
EYFP single-labeled or unlabeled resident striatal neurons.
We found that newly generated striatopallidal projection neurons
(EYFP+/CT-B+ neurons; n = 4) exhibited electrophysiological
characteristics analogous to those of existing MSNs that had
similarly incorporated the retrograde tracer (EYFP/CT-B+; n =
5) and to unlabeled striatal neurons defined only by their
morphology (n = 10) (Figures 4B and 4C). Analysis of the resting
membrane potential, the frequency of action potentials, and the
maximal amplitude of action potentials revealed no significant
differences among the three different groups of cells recorded
in 8-week-old wild-type mice (Figure 4D and Table S4). Thus,
the newly generated MSNs developed functional striatopallidal
projections and exhibited electrophysiological responses analo-
gous to those of preexisting resident MSNs.
Newly Generated Neurons in R6/2 HD Mice Integrate As
Functional Striatopallidal Neurons
To assess the functional integration as evidenced by the electro-
physiological competence of newly generated neurons in HD
mice, nestin-CreERT2/ROSA-EYFP mice were crossed with
R6/2 mice. These mice were then subjected to the same
experimental paradigm as their bigenic wild-type counterparts
(Figure 4A). As with the wild-type mice, electrophysiological
recordings of newly generated EYFP+/CT-B+ neurons that suc-
cessfully extended pallidal projections (n = 6 recorded) were
compared both to neurons that had incorporated the retrograde
tracer (EYFP/CT-B+; n = 4) and to unlabeled neurons (EYFP/
CTB; n = 7). The resting membrane potential, as well as the
action potential thresholds and maximal amplitudes thereof,
were similar in R6/2 and wild-type mice. Interestingly though,
the newly generated EYFP+/CT-B+ neurons of R6/2 mice
Figure 4. BDNF/Noggin-Induced MSNs Functionally Integrate into the R6/2 Striatum
(A) Experimental design: 4-week-old tamoxifen-pretreated nestin-CreERT2/ROSA26-CAG-EYFP (wild-type) or nestin-CreERT2/ROSA-CAG-EYFP/R6/2 (R6/2)
mice were given 2 week intraventricular infusions of BDNF and noggin proteins, followed 1 week later by intrapallidal injection of the retrograde tracer Alexa Fluor
594-conjugated CT-B. (B) Example of EYFP+/CT-B+ double-labeled neuron targeted for recording of field potentials. Arrow indicates the pipette used for whole-
cell patch-clamp recording and filled with Alexa Fluor 350 for subsequent confirmation of the analyzed cells. (C) Representative action potentials recorded from a
newly generated neuron (EYFP+/CT-B+) that had incorporated the retrograde cholera toxin-B tracer. (D) Comparisons of membrane potential, firing frequency,
and amplitude in all three categories of recorded striatal neurons, in both wild-type and R6/2 mice. One-way ANOVA with Bonferroni post hoc t tests; mean ±
SEM; n/s, not significant; *p < 0.05. (E) Excitatory postsynaptic potentials (EPSPs) were also recorded on patched neurons of both wild-type and R6/2 mice.
(F) No significant differences were noted in the amplitude or frequency of EPSPs of newly recruited neurons (EYFP+/CT-B+), when they were compared to either
preexisting MSNs that incorporated the retrograde tracer (EYFP/CT-B+) or resident unlabeled neurons. One-way ANOVA with Bonferroni post hoc t tests;
mean ± SEM; n/s, not significant; *p < 0.05. Scale bar: (B), 10 mm. See also Figure S3 and Tables S4A and S4B.
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Figure 5. Newly Recruited MSNs Have
Reduced Neuronal Intranuclear Inclusions
Serial brain sections from a 12-week-old
tamoxifen- and AAV4-BDNF/noggin-treated
nestin-CreERT2/ROSA-EYFP/R6/2 mouse were
immunostained with anti-huntingtin EM48 anti-
bodies (red), identifying neuronal intranuclear
inclusions, and DARPP-32 (blue) and EYFP
(green). (A) Inclusions were absent from nestin-
EYFP+ progenitor cells of the subventricular zone.
Str, neostriatum; LV, lateral ventricle. (B) New
neurons (arrows), arising from the SVZ, do not
initially harbor nuclear inclusions (arrowhead). (C)
Stereological counts of neuronal intranuclear in-
clusions (NII) showed that less than one-third of
newly generated neurons harbored NII when as-
sessed, whereas over two-thirds of EYFP stable
MSNs did so, whether in AAV4-BDNF/noggin-
treated or untreated R6/2 mice. One-way ANOVA
with Bonferroni post hoc tests; mean ± SEM; *p <
0.05, **p < 0.01. Scale bars: (A), 25 mm; (B), 10 mm.
See also Figure S4.
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during current injection than did preexisting (EYFP/CT-B±) neu-
rons (33.3 ± 5.4 Hz for EYFP+/CT-B+ neurons, versus 17.5 ±
1.7 Hz and 19.3 ± 3.0 Hz for EYFP/CT-B+ and unlabeled neu-
rons, respectively; mean ± SEM; p < 0.05 by one-way ANOVA
with Bonferroni post hoc tests) (Figure 4D and Table S4A). Since
we noted no such difference in action potential frequency
between newly generated and preexisting MSNs in wild-type
mice, it would seem unlikely that this is either a fundamental
distinction of newly generated adult neurons or a function of their
relative immaturity. Rather, these data suggest that the higher
action potential frequency among the recorded new neurons
may reflect some difference in their membrane properties
compared to those of established resident neurons of the R6/2
striatum, even at this relatively early 8 week time point. Together,
these data indicate that BDNF/noggin-induced, newly generated
striatopallidal neurons extended axons to the globus pallidus
and were fully capable of generating trains of action potentials
in both wild-type and R6/2 mice.
To further establish whether AAV4-BDNF/noggin-recruited
new neurons fully integrated in the R6/2 brain, we next asked if
they received afferent input. We found that adult-generated
EYFP+/CT-B+ striatopallidal neurons indeed exhibited excitatory
postsynaptic potentials (EPSPs) and that they did so in both
wild-type and R6/2 mice. In both the wild-type and R6/2 mice,
the EPSPs of newly generated EYFP+/CT-B+ neuronswere indis-
tinguishable from those of both EYFP/CT-B+ and unlabeled
stable resident striatal neurons (Figures 4E and 4F and Table
S4B). These observations suggest that the excitatory synaptic
input to newly generated MSNs is indistinguishable from that
of resident MSNs and further confirm that these new neurons
effectively integrate into the existing striatopallidal circuitry.
Newly Generated Striatal Neurons in Adult R6/2 Mice
Contain Fewer Intranuclear Inclusions
Neuronal intranuclear inclusions (NIIs) are aggregates of mutant
huntingtin, the abundance of which correlates with cellular atro-794 Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc.phy and death in HD (Bates, 2003; Becher et al., 1998; Hickey
and Chesselet, 2003). Using an antibody (EM48) that recognizes
the N-terminal portion of huntingtin protein, NIIs were first visu-
alized in both the striatum and cortex of R6/2 mice at 3.5 weeks
of age (Meade et al., 2002). This finding suggests that NIIs are not
present at birth in R6/2 mice and instead only appear after a
period of postnatal differentiation. This was similarly evident
within the young neuronal progeny of SVZ neural stem cells, in
which we noted an absence of nuclear inclusions (Figure 5A).
Since newly generated neurons arise from mitotic SVZ progeni-
tors, and since mutant huntingtin preferentially accumulates as a
function of postmitotic cellular age (Gutekunst et al., 2002), we
postulated that new neurons might arise without preexisting
NIIs. To test this hypothesis, serial brain sections from tamox-
ifen-pretreated AAV4-BDNF/noggin-treated nestin-CreERT2/
ROSA-EYFP/R6/2 mice were immunostained with EM48
antibody (see Figure S5A for design). Stereological analysis
showed that newly generated MSNs, coexpressing DARPP-32
and EYFP, contained significantly fewer EM48+ NIIs than did
stable EYFP/DARPP-32+ resident neurons in the same
animals (31.0% ± 9.6% versus 68.7% ± 9.6%, respectively;
mean ± SEM; p < 0.05 by one-way ANOVA with Bonferroni tests;
Figures 5B and 5C). Indeed, less than one-third of adult-gener-
ated striatal neurons contained inclusions by 12 weeks, a time
point by which over two-thirds of resident neurons had already
developed inclusion pathology. Thus, BDNF/noggin-induced
adult-generated MSNs first developed intranuclear inclusions
only after several months of postmitotic ontogeny, suggesting
the relative (if transient) protection of newly generated neurons
from mutant huntingtin-associated pathology.
New Neurons Can Be Generated in the Neostriatum
of the Adult Squirrel Monkey
The ability of AAV4-BDNF/noggin treatment to induce and
sustain the addition of new neurons to the HD neostriatum,
and to extend both motor performance and survival in affected
mice, suggested the potential for using this strategy as a
Figure 6. Adenoviral BDNF/Noggin Triggered Neuronal Addition to the Adult Monkey Striatum
(A) Sections of a squirrel monkey brain, from an animal killed 8 weeks after intraventricular injection of adenoviral EGFP, revealed EGFP expression limited to the
ependymal cell layer of the lateral ventricle; no parenchymal expression of EGFP was noted.
(B–F) Striatal sections of an AdBDNF/Adnoggin-treated monkey were coimmunolabeled for BrdU (green) together with the neuronal markers Dcx (B), ßIII-tubulin
(C and D), NeuN (E), and DARPP-32 (F) (red). In (C), many BrdU+ apparent neuronal migrants were found abutting the adluminal surfaces of striatal blood vessels.
(G) Newly generated ßIII-tubulin+ neurons, identified by their incorporation of BrdU, were abundant yet limited to the striata of AdBDNF/noggin-treated animals
(mean ± SEM). No evidence of striatal neurogenesis was noted in AdNull-treated controls.
LV, lateral ventricle; F, fimbria; Ca, Caudate; Cc, corpus callosum; VAT, ventral anterior thalamus. Scale bars: (A): 500 mm, (C): 50 mm, (B), (D), (E), and (F): 10 mm.
See also Figure S5.
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whether nonhuman primates might also have sufficient
numbers of accessible subependymal progenitors to similarly
respond to BDNF and noggin with heterotopic striatal neuronal
addition (Bedard et al., 2005). To that end, we injected adult
squirrel monkeys with adenoviral overexpression vectors for
BDNF and noggin. We used adenovirus rather than AAV
for this small study so as to maximize the levels of CSF
BDNF and noggin; our question here was whether we could
induce significant striatal neuronal addition in primates, as
opposed to whether we could sustain it for maximal therapeutic
benefit.To transduce adult monkeys to overexpress ventricular BDNF
and noggin, we used CT (computed tomography) guidance to
deliver either an AdBDNF/AdNoggin mixture (20 ml/injection,
containing AdBDNF 1.73 3 1013 particles/ml and AdNoggin
1.93 1013 particles/ml, 1:1) or AdEGFP (AdNull, in similar volume
and titer) into each lateral ventricle (n = 3 monkeys). Beginning
1 week later, the animals received BrdU injections (75 mg/kg)
for 15 days. Eight weeks after the viral injection, the monkeys
were sacrificed and their brains were processed for histology.
Control animals injected with AdNull (n = 3) showed marked
expression in the ependymal walls of the lateral ventricles (Fig-
ure 6A). In AdBDNF/noggin-treated animals, CSF BDNF wasCell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc. 795
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protein; mean ± SEM), while noggin measured 1.1 ± 0.2 ng/ml
(0.8 ± 0.05 pg/mg protein; mean ± SEM). These levels are within
the dose range appropriate for eliciting BDNF-induced striatal
neurogenesis, as we have previously shown in rodents (Chmiel-
nicki et al., 2004).
In the AdBDNF/noggin-treated monkey striata, confocal
microscopy demonstrated abundant BrdU-incorporating neu-
rons; these newly generated neurons coexpressed Dcx, ßIII-
tubulin, NeuN, and/or DARPP-32, and colabeling for each
marker was confirmed as such by confocal imaging with orthog-
onal views (Figures 6B–6F). Many BrdU+/Dcx+ and BrdU+/bIII-
tubulin+ cells in particular were noted as apparent migrants along
striatal blood vessels (Figures 6B and 6C). Importantly, BrdU+
neurons were found only in the striata of AdBDNF/noggin-
treated animals (70.9 ± 13.7 ßIII-tubulin+/BrdU+ cells/mm3
mean ± SEM); no BrdU+ neurons were noted in any AdNull-
treated monkey striata (Figure 6G). Thus AdBDNF/noggin stimu-
lated the addition of new cells that expressed antigenic markers
of both migrating neuroblasts and mature MSNs, thereby high-
lighting the potential use of BDNF/noggin-induced striatal neuro-
genesis as a therapeutic strategy for HD.
DISCUSSION
In this study, we found that the intraventricular delivery of AAV4-
BDNF and AAV4-noggin was sufficient to induce and sustain
striatal neuronal recruitment from endogenous neural progenitor
cells in R6/2 huntingtin mutant mice, that the newly generated
neurons developed as MSNs and became both anatomically
and functionally integrated into striatopallidal circuits, and that
their production slowed disease progression and extended the
survival of these HD mice. The newly generated neurons
included both enkephalin and substance-P-expressing cells,
which define neurons of the indirect and direct striatofugal path-
ways, respectively; these were added in roughly equal propor-
tions, suggesting the reconstitution of each major pool of striatal
projection neurons. By fate-mapping subependymal neural stem
and progenitor cells using nestin-CreERT2/ROSA26/EYFP
bigenic and nestin-CreERT2/ROSA-EYFP/R6/2 trigenic mice,
we then confirmed that the newly generated MSNs arose from
nestin-derived progeny in both wild-type and HD mice. By
combining this strategy with intrapallidal injection of a retrograde
tracer, and then using two-photonmicroscopy of striatal slices to
identify adult-generated striatopallidal neurons for patch-clamp
analysis, we further confirmed that AAV4-BDNF/noggin-induced
nestin-CreERT2/ROSA-EYFP-tagged neurons successfully
extended projections to the globus pallidus and functionally inte-
grated into the existing striatopallidal circuitry. On the basis of
these findings, we then assessed the utility of this strategy in
mediating neuronal addition to the adult primate striatum, using
adenoviral delivery to overexpress BDNF and noggin in the ven-
tricular walls of adult squirrel monkeys. We found that just as in
mice, monkeys harbor a progenitor population able to respond
to local noggin and BDNF overexpression with heterotopic
neuronal addition to the normal adult neostriatum.
AAV4 proved an appropriate and effective long-term expres-
sion vector, with widespread yet phenotype-specific ependymal
transduction in both wild-type and R6/2 mice, as previously796 Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc.noted in other systems (Benraiss and Goldman, 2011; Benraiss
et al., 2012; Davidson et al., 2000; Dodge et al., 2010; Liu et al.,
2005). Importantly, AAV4’s restricted tropism toward ependymal
cells permitted the sustained exposure of subependymal neural
stem cells and their progeny to BDNF and noggin, without them-
selves being directly transduced. This exquisite phenotypic and
regional specificity proved critical; indeed, we have observed
that neuronal recruitment to the olfactory bulb falls when BDNF
expression vectors are injected directly into the subependyma
(data not shown), an approach that transduces the progenitors
themselves to overexpress the transgenes of interest (Henry
et al., 2007; Reumers et al., 2008). The distinct results achieved
using ependymal versus subependymal transduction by BDNF
expression vectors suggests that such autocrine expression
may have very different effects on neural stem and progenitor
cell fate than the transient ‘‘next-door neighbor’’ exposure pro-
vided by ependymal transduction.
To directly visualize those neurons generated in res-
ponse to BDNF and noggin, we used tamoxifen-inducible
nestin-CreERT2/ROSA-EYFP reporter mice to label subepen-
dymal neural stem and progenitor cells and their progeny; these
mice exhibit permanent reporter gene expression by all cells
derived from those cells that were nestin-expressing at the
time of tamoxifen exposure. As such, they allow the specific
identification, lineage tracing, and anatomical tracking of those
neurons newly generated in adulthood. By inducing Cre recom-
bination and then treating with BDNF and noggin (delivered by
AAV4, as well as proteins in separate experiments using osmotic
minipump), we found that newly generated striatal EYFP+ neu-
rons coexpressed a combination of markers that typify MSNs,
including bIII-tubulin, NeuN, and DARPP-32. Thus, our nestin-
CreERT2/ROSA-EYFP/R6/2 trigenic HD reporter mice con-
firmed that BDNF and noggin treatment induced the striatal
recruitment of new neurons from nestin-expressing neural
stem and progenitor cells.
Our functional data suggest that these newly added neurons
may be able to functionally complement those lost in HD. In
particular, our electrophysiological analysis of newly generated
EYFP+ MSNs in both 60-day-old wild-type and R6/2 mice
revealed that these new projection neurons were functionally
competent and integrated, receiving afferent input as well as
generating both spontaneous and stimulus-evoked trains of
action potentials. Interestingly, previous studies have similarly
shown that MSNs of presymptomatic HD mouse models—
including R6/2—have electrophysiological profiles identical to
wild-type mice, although they diverge at terminal stages of
the disease (90 days) (Andre´ et al., 2011; Klapstein et al.,
2001). Our analysis confirmed that the electrophysiological
properties and network integration of existing unlabeled
MSNs at 60 days were comparable in wild-type and R6/2
mice. In addition, the identification of striatal nestin-EYFP+
MSNs backfilled by CT-B injected into the globus pallidus
also enabled us to compare the electrophysiological properties
of newly generated neurons with those of their preexisting, sta-
bly resident counterparts. This analysis suggested that newly
generated MSNs in both wild-type and R6/2 mice received
functional inputs—as reflected in their EPSPs—and generated
action potentials in a manner virtually indistinguishable from
that of existing MSNs.
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repeats, which we verified in all mice using PCR across the
repeat region. In these mice, symptom onset begins as early
as 8–9 weeks; by 12 weeks, affected mice manifest a resting
tremor and ataxia, startle myoclonus, and seizures, and they
typically die by 16–17 weeks of age. In contrast, our AAV4-
BDNF/noggin-treated mice just began to exhibit deteriorating
motor skills by that age, and lived an average of 33.5% longer
than did their controls, with outliers living as long as twice the
maximal life span of any controls. The survival advantage asso-
ciated with induced neuronal production may be limited by the
effective functional life span of the newly generated neurons,
which also express the polyglutamine expansion of mutant hun-
tingtin. Yet our data indicate that subependymal progenitors do
not express neuronal intranuclear inclusions and that newly
generated neurons only slowly accumulate these markers of
cytopathology. Thus, whereas most resident MSNs manifested
pronounced intranuclear inclusions by 12 weeks of age, less
than one-third of newly generated neurons did so by that point
(Figure 5). These observations suggest that newly generated
neurons have a discrete window of time during which they
may functionally integrate and compensate for impaired resident
neurons before they themselves succumb to HD pathology.
This in turn suggests the potential utility of a long-lasting and/
or repetitive induction of striatal neuronal addition as a means
of long-term disease management. This may be accomplished
through the use of long-term expression vectors, such as
AAV4, or by the intermittent delivery of BDNF and noggin
proteins; in this paper, we have reported examples of both deliv-
ery strategies, each of which effectively stimulated neuronal
recruitment.
Thus, the sustained AAV4-mediated delivery of BDNF and
noggin to the adult R6/2 brain was associated with both
enhanced neurogenesis and delayed disease progression. The
neurons generated from this approach arose from subependy-
mal progenitors and extended axons to their normal develop-
mental targets, achieving electrophysiological network integra-
tion and compensating for the function of neurons lost to the
disease process. The extended functional competence and sur-
vival of the AAV4-BDNF/noggin-treated R6/2 mice thus presents
a unique example of induced compensatory neuronal replace-
ment as a means of treating an adult neurodegenerative disor-
der. R6/2 is but a single model, though, which manifests only
mutant exon 1 expression and may then recapitulate HD pathol-
ogy differently than do full-lengthmutant huntingtinmodels. Clin-
ical translation of this approach thus demands its validation in
other models of HD and, in particular, in transgenic models of
full-length mutant huntingtin (Gray et al., 2008; Southwell et al.,
2013; Yu-Taeger et al., 2012), especially those with shorter,
more clinically representative CAG repeat expansions than the
105 CAG repeats borne by the R6/2 mice used in our present
study. Nonetheless, given the persistence of competent neural
stem and progenitor cells in the adult human brain (Kirschen-
baum et al., 1994; Pincus et al., 1998; Sanai et al., 2004), and
the apparent responsiveness to BDNF and noggin of these pro-
genitors in the adult nonhuman primate brain (Figure 6), paired
with the favorable safety profile of AAV vectors in several human
clinical trials (Christine et al., 2009; LeWitt et al., 2011; Mueller
and Flotte, 2008), we believe that our data suggest the feasibilityof induced striatal neuronal addition as a viable therapeutic strat-
egy for HD.EXPERIMENTAL PROCEDURES
Animals and Viral Injection
This study was approved by the University Committee on Animal Resources of
the University of Rochester. Wild-type females with ovary transplants from
R6/2+ (105 CAG) mice were purchased from Jackson Laboratories. Mice
were genotyped after weaning; we analyzed those that were R6/2 transgenic
positive to determine their CAG repeat number by PCR, with primers encoding
a product spanning the repeat region (forward primer 50-ATGAAGGCCTTC
GAGTCCCTCAAGTCCTTC-30 and reverse 50-GGCGGCTGAGGAAGCTG
AGGA-30). Only mice with confirmed 105 ± 5 CAG repeats were used for this
study.
Adeno-associated viruses (AAV4) expressing BDNF and noggin were
produced at the University of Iowa Gene Transfer Vector Core, as described
(Benraiss et al., 2012). For all experiments, R6/2 mice received bilateral intra-
ventricular 1.5 ml injections of a 1:1 mixture of AAV4-BDNF and AAV4-
DB2noggin (referred to as AAV4-BDNF/noggin), AAV4-Null, or saline at
4 weeks of age. Beginning 2 weeks later, mice were treated with BrdU
(75 mg/kg, i.p.) for 30 days, then killed 2 weeks later for histological analysis.
Both our stereotaxic injection and BrdU labeling protocols are further detailed
in the Supplemental Experimental Procedures.
Six male adult squirrel monkeys, weighing between 700 and 1,200 g, were
injected with 20 ml of either an adenoviral-BDNF/adenoviral-noggin mixture
or a control adenoviral-EGFP into the lateral ventricles (n = 3 monkeys
each), using stereotaxic coordinates determined through computerized
tomography scanning of each animal. Beginning 1 week following adenoviral
injection, the monkeys received daily intravenous injections of BrdU
(75 mg/kg, IV) for 15 days, to label newly generated neurons. Five weeks later,
the animals were killed and their brains were dissected, cryosectioned, and
immunostained for analysis.
Identifying Newly Generated Neurons in Nestin-CreERT2/ROSA26-
EYFP Mice
Nestin-CreERT2/ROSA26-EYFP bigenic mice were used experimentally or
bred (Imayoshi et al., 2006, 2008) with females with ovary transplants from
R6/2+ (105 CAG) mice. At three weeks of age, the mice received daily injec-
tions of tamoxifen (2.5 mg i.p., or 125 mg/kg) for 10 days. The tamoxifen
stock solution was prepared by suspending 250 mg tamoxifen (Sigma;
T5648) in 1 ml of ethanol followed by the addition of 9 ml peanut oil. The
mice were injected with AAV4 1 day after their last tamoxifen injection,
when 4 weeks old. A subset of these nestin bigenic or trigenic mice (n = 4
each) also received a stereotaxic intrapallidal injection of the fluorescent-
conjugated retrograde tracer CT-B, conjugated to Alexa Fluor 555 (0.5 ml;
Invitrogen; C-34776). The injections were given 1 week prior to sacrifice at
12 weeks, at the following coordinates relative to bregma: AP 0.8 mm;
ML ± 2.25 mm; DV 3.6 mm.
Analogous bigenic and trigenic reporter mice established with mEGFP were
established to permit whole-cell visualization of both newly generated and
resident MSNs. The construction of these mice, and of corresponding lentivi-
ral-mEGFP vectors, is described in the Supplemental Experimental
Procedures.
Immunolabeling
Immunophenotyping of newly generated and resident MSNs was accom-
plished using a panel of antigenic markers that included Dcx, ßIII-tubulin,
NeuN, DARPP-32, and substance P and enkephalin, typically colabeled with
one another or for BrdU; detailed protocols for each of these immunostains
are provided in the Supplemental Experimental Procedures.
Electrophysiological Assessment
Physiological recordings of newly generated neurons in slice preparations of
nestin-EYFP bigenic wild-type and crossed R6/2 trigenicmice were performed
as described in detail in the Supplemental Experimental Procedures.Cell Stem Cell 12, 787–799, June 6, 2013 ª2013 Elsevier Inc. 797
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In striatal sections, cells that were double-labeled with BrdU or GFP and
markers described were selected for confocal analysis. Images were acquired
using an Olympus Fluoview confocal microscope and an argon-krypton laser
and analyzed as previously described (Benraiss et al., 2001; Chmielnicki et al.,
2004; Cho et al., 2007). More detailed methods and scoring criteria are
described in the Supplemental Experimental Procedures.
Scoring and Quantification
Counts of striatal BrdU+ cells were scored by antigenic phenotype using ste-
reological methodology for unbiased estimation across the striatal volume as
detailed in the Supplemental Experimental Procedures.
Rotarod Performance
Motor coordination and balance weremeasured using rotarod analysis as pre-
viously described (Cho et al., 2007) and as detailed in the Supplemental Exper-
imental Procedures.
Survival
The viabilities of AAV4-BDNF/noggin, AAV4-Null, or saline-treated R6/2 mice
were assessed twice daily throughout the entire length of the experiment. At
least one wild-type littermate was provided in each experimental cage, and
no mice entered into the survival study were subjected to behavioral tests
so as to exclude the possibility of any confounding effects of such tests
upon net life span. Survival data were analyzed by Kaplan-Meier survival
curves.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes Supplemental Experimental
Procedures, six figures, and four tables and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2013.04.014.
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